LL-37 (Cathelicidin) vs SNAP-8
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
LL-37 (Cathelicidin)
LL-37 is the only human cathelicidin antimicrobial peptide. It plays crucial roles in innate immunity and has shown diverse biological activities including antimicrobial, immunomodulatory, and wound healing properties.
Full details →SNAP-8
SNAP-8 (Acetyl Octapeptide-3) is a cosmetic peptide that reduces the appearance of wrinkles by modulating muscle contraction. It is often called 'topical Botox' though it works through a different mechanism.
Full details →Side-by-Side Comparison
| Aspect | LL-37 (Cathelicidin) | SNAP-8 |
|---|---|---|
| Dose Range | 500 mcg–1.6 mg | 500 mcg–1 mg |
| Frequency | 1x daily | 1x daily |
| Cycle Length | 2–4 weeks | 4–8 weeks |
| Route | topical | topical |
| Mechanism | Disrupts bacterial membranes, neutralizes endotoxins, modulates immune cell function, and promotes wound healing. Has both direct antimicrobial and immunomodulatory effects. | Mimics the N-terminal end of SNAP-25, competing with native SNAP-25 for position in the SNARE complex. This reduces neurotransmitter release at the neuromuscular junction, decreasing muscle contraction. |
| Typical Dosage | Research protocols vary widely. Typical ranges: 50-200mcg administered subcutaneously 2-3 times weekly. Some protocols use higher doses for acute infections. | Topical: 3-10% concentration in serums or creams, applied 1-2 times daily to target areas (forehead, crow's feet, etc.). |
| Administration | Subcutaneous injection. Can cause significant injection site reactions. Often used in conjunction with other immune-supporting protocols. | Topical application only. Should be applied to clean skin. Often formulated with penetration enhancers for better absorption. |
| Side Effects | Injection site pain and reactions are common. May cause flu-like symptoms, temporary fatigue, or immune activation responses. | Generally well-tolerated topically. Rare reports of mild skin irritation. No systemic effects at cosmetic doses. |
| Best For |
Key Differences
Unique to LL-37 (Cathelicidin):
Unique to SNAP-8:
Key Studies
LL-37 (Cathelicidin)
- Cathelicidin LL-37 Expression in Human Breast Implant Capsules.
Plastic and reconstructive surgery, 2024
- Salivary Cathelicidin (LL-37) in Children and Adolescents Living with HIV.
Biomedicine hub, 2024
- Antifungal properties of cathelicidin LL-37: current knowledge and future research directions.
World journal of microbiology & biotechnology, 2023
Ready to Learn More?
Looking for trusted sources?